The EAS Anitschkow Prize is the Society’s most prestigious distinction, awarded to outstanding scientists in the area of atherosclerosis and linked metabolic disturbances. The recipient of the Prize receives the Anitschkow Medal, an award of ten thousand Euros in recognition of their contribution to the study of atherosclerosis, presents the Anitschkow Lecture as part of the Opening Ceremony at EAS Congress, and is invited to write a review for the Society’s Journal, Atherosclerosis.
Dr. Paul M. Ridker, MD, MPH
Prof. Ridker is a global leader in atherosclerosis research, renowned for his groundbreaking work on inflammation as a central factor in atherosclerosis, including the pivotal CANTOS trial and his development of hsCRP as a key biomarker of cardiovascular disease.
Over a remarkable 30-year career, Dr. Ridker and his collaborators have made groundbreaking contributions to cardiovascular medicine, including:
- Providing the first proof-of-principle for the inflammation hypothesis of atherothrombosis in humans.
- Demonstrating that statin therapy is both lipid-lowering and anti-inflammatory.
- Developing the first FDA-approved diagnostic test for vascular inflammation (hsCRP).
- Identifying the first proven anti-inflammatory treatment for heart disease (canakinumab).
- Introducing the concept of “residual inflammatory risk” into clinical practice worldwide.
